The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | The current outcomes of patients with T-cell lymphoma and the unmet needs that remain
In this video, Olivier Tournilhac, MD, PhD, Clermont-Ferrand University Hospital, Clermont-Ferrand, France, briefly comments on the current clinical outcomes observed in patients with T-cell lymphoma, highlighting the results of the long-term analysis of the Allo-Allo Tandem Bone Marrow Transplant (AATT) trial (NCT00984412). Prof. Tournilhac emphasizes the need for novel therapeutic approaches and bridging strategies for this patient population. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
